Showing results (421-430 of 785) with videos related to

Sort By:
Pageof 79
The Lancet. HIV|December 18, 2018
Safety of elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in HIV-1-infected adults with end-stage renal disease on chronic haemodialysis: an open-label, single-arm, multicentre, phase 3b trialJoseph J Eron, Jean-Daniel Lelievre, Robert Kalayjian, et al.
The Lancet. HIV|December 1, 2019
On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trialGuillemette Antoni, Cécile Tremblay, Constance Delaugerre, et al.
The Lancet. HIV|February 10, 2019
Clinical effect and cost-effectiveness of incorporation of point-of-care assays into early infant HIV diagnosis programmes in Zimbabwe: a modelling studySimone C Frank, Jennifer Cohn, Lorna Dunning, et al.
The Lancet. HIV|February 7, 2019
Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration
The Lancet. HIV|December 25, 2019
Addressing the global burden of hepatitis B virus while developing long-acting injectables for the prevention and treatment of HIVRobert C Bollinger, Chloe L Thio, Mark S Sulkowski, et al.
The Lancet. HIV|February 23, 2018
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration studyBeatriz Grinsztejn, Brenda Hoagland, Ronaldo I Moreira, et al.
The Lancet. HIV|July 17, 2017
Xpert HIV-1 point-of-care test for neonatal diagnosis of HIV in the birth testing programme of a maternity hospital: a field evaluation studyKarl-Günter Technau, Louise Kuhn, Ashraf Coovadia, et al.
The Lancet. HIV|March 2, 2018
Migration and risk of HIV acquisition in Rakai, Uganda: a population-based cohort studyOluwasolape Olawore, Aaron A R Tobian, Joseph Kagaayi, et al.
The Lancet. HIV|October 22, 2016
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trialAditya H Gaur, Hilda Kizito, Wasana Prasitsueubsai, et al.
The Lancet. HIV|December 14, 2016
Trends in the burden of HIV mortality after roll-out of antiretroviral therapy in KwaZulu-Natal, South Africa: an observational community cohort studyGeorges Reniers, Sylvia Blom, Clara Calvert, et al.
Pageof 79